stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) EV/Sales
As of 5 November 2026, Denali Therapeutics Inc. (DNLI) trades at a EV/Sales of 143×. Over the past ten years it has ranged from 0.0× (December 2018) to 390× (December 2020); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 5.9× | (70.70%) |
| FY2022 | 20.1× | (78.75%) |
| FY2021 | 94.8× | 312.13% |
| FY2020 | 23.0× | (53.47%) |
| FY2019 | 49.4× | 340.67% |
| FY2018 | 11.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 149× | 985.96% |
| Jun 2026 | 13.8× | 133.05% |
| Dec 2023 | 5.9× | 21.05% |
| Sep 2023 | 4.9× | (42.36%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TLX Telix Pharmaceuticals Limited compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.2× |
| IDYA IDEAYA Biosciences, Inc. compare | 63.7× |
| VRDN Viridian Therapeutics, Inc. compare | 91.0× |
| DNLI Denali Therapeutics Inc. | 143× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement